Medical/Pharmaceuticals

XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals

SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 c...

2025-09-09 20:42 2074

Dizal Showcases Robust Portfolio of Lung Cancer Studies at 2025 WCLC

SHANGHAI, Sept. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced the presentation of new findings on its leading assets, ZEGFROVY® (sunvozertinib) and golidocitinib, in...

2025-09-09 18:00 1233

WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry

* End-to-end Green CRDMO solutions to enable global clients for broader positive impact * Span from biologics research, development, manufacturing, and overall operations * Integration with lean management and digitalization for continuous excellence * A comprehensive ecosystem featuring ...

2025-09-09 18:00 2499

LISCure BioSciences Secures World's First FDA NDI notification for Hair Health Probiotic Mobiome®

SEOUL, South Korea, Sept. 9, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") today announced thatMobiome®, its proprietary hair health probiotic, has receivedNew Dietary Ingredient (NDI) Notification from the U.S. Food and Drug Administration (FDA) —the first such recognition worldwide for ...

2025-09-09 13:41 1317

Elevating Healthcare Innovation: ICP DAS-BMP Brings Advanced TPU Portfolio at Medtec China 2025

HSINCHU, Sept. 9, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation in Medtec China 2025, to be held fromSeptember 24 to 26 at the Shanghai World Expo Exhibit...

2025-09-09 09:45 1352

Sirtex Receives Expanded CE Mark Approval for SIR-Spheres® Y-90 Resin Microspheres

Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of minimally invasive interventional oncology solutions, today announced that it has received an...

2025-09-08 21:00 1151

Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London

PISCATAWAY, N.J., Sept. 8, 2025 /PRNewswire/ -- Cell and gene therapies (CGT) are advancing rapidly and are reshaping the future of medicine. From CRISPR-based genome editing to new applications of in vivo and ex vivo cell therapies, scientific breakthroughs are increasingly moving from the labor...

2025-09-08 20:49 1175

SpaceGut's Precision AI System for Gut Testing Achieves Up to 87% Improvement in Irritable Bowel Syndrome Management

KUALA LUMPUR, Malaysia, Sept. 8, 2025 /PRNewswire/ -- SpaceGut , Malaysia's first AI-powered at-home Gut Microbiome Test Kit

2025-09-08 20:37 1810

Medit Expands Orthodontic Suite with Launch of Medit Aligners: Premium Comfort, Precision, and Speed for Modern Orthodontics

NEWPORT BEACH, Calif., Sept. 8, 2025 /PRNewswire/ -- Medit, a global leader in digital dentistry solutions, today announced the launch ofMedit Aligners, a premium digital clear aligner solution designed to deliver faster turnaround times and more predictable outcomes for orthodontic patients. ...

2025-09-08 20:30 1401

WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year

SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has received the Gold Medal by EcoVadis sustainability rating for the s...

2025-09-08 20:00 1339

BrainCo Helps Amputee Showcase Technology at WAIC 2025

BOSTON, Sept. 8, 2025 /PRNewswire/ -- At the 2025 World Artificial Intelligence Conference (WAIC) inAugust 2025, Gu demonstrated the BrainCo Intelligent Bionic Hand. He played the piano with precision and even explained to attendees how brain-computer interface (BCI) technology enables amputees t...

2025-09-08 19:29 1107

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens , the leader in non-invasive liver diagnostics, is...

2025-09-08 18:00 1134

Remplir™ Study Delivers Compelling 81% Success Rate

Data to support US sales roll out and EU + UK regulatory submissions  * Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. * Real World Evidence (RWE) patient data collected in the study confirms Ortho...

2025-09-08 17:32 1477

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

* Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company * KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA * Acquisition strengthens ...

2025-09-08 15:49 837

Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion

GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue ofRMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year...

2025-09-08 15:35 5077

Siriraj × MIT Hacking Medicine 2025 Now Open for Applications Across Southeast Asia: A Call for Innovation to Tackle Greatest Healthcare Challenges

BANGKOK, Sept. 8, 2025 /PRNewswire/ -- Siriraj Hospital and MIT Hacking Medicine have joined forces once again to host the second edition of their medical innovation hackathon, Siriraj × MIT Hacking Medicine 2025, taking place fromOctober 31 to November 2, 2025. Applications are now open for part...

2025-09-08 14:39 2157

Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines

HONG KONG, Sept. 7, 2025 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; Stock Code: 2257), a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, today announced that it has entered into a stra...

2025-09-08 12:15 1119

Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines

SHANGHAI, Sept. 7, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a$60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Pa...

2025-09-08 10:00 1260

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

* The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 * In the North American patients, the OS HR was 0.70 * The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) ...

2025-09-07 18:08 1729

Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC

HANGZHOU, China, Sept. 5, 2025 /PRNewswire/ -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting receptor ty...

2025-09-05 21:38 2605
1 ... 40414243444546 ... 644

Week's Top Stories